Behind The Most Exciting Stock Pop In Years!
Summary
Hosts Travis Hoey, Lou Whiteman, and Rachel Warren analyze Target’s earnings, noting improved fundamentals but questioning its long-term strategy and valuation. They discuss Moderna’s 135% surge following promising Phase 3 results for a personalized cancer vaccine, while cautioning about scaling challenges. Finally, they examine OpenAI’s slowing growth and widening losses alongside Anthropic’s rapid expansion, highlighting the race for potential IPOs in the competitive AI sector.
Topics discussed
Target earnings analysis: Turnaround progress and valuation concerns
Ad breaks: Range Rover Sport and Schwab trading platform
Moderna's mRNA cancer vaccine trial results and stock surge
Ad breaks: Vanguard Investor Choice and Claude AI
OpenAI and Anthropic growth metrics, losses, and IPO race
Listen ad-free on Castria